{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:22:31Z","timestamp":1758050551186,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.bulcan.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T15:26:04Z","timestamp":1681140364000},"page":"S29-S39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Deuxi\u00e8me allogreffe (mise \u00e0 jour). Recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle osseuse et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"111","author":[{"given":"Nabil","family":"Yafour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Borel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Coman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Fayard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavroula","family":"Masouridi-Levrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11s","key":"10.1016\/j.bulcan.2023.03.005_bib0235","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.005_bib0240","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bmt.2014.300","article-title":"Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT","volume":"50","author":"Sauer","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2023.03.005_bib0245","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.005_bib0250","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2023.03.005_bib0255","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.15973","article-title":"Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the acute leukaemia working party of the european Society for Blood and Marrow Transplantation","volume":"186","author":"Nagler","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.03.005_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.08.008","article-title":"Efficacy of a Second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis","volume":"28","author":"Kharfan-Dabaja","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.bulcan.2023.03.005_bib0265","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41409-021-01271-4","article-title":"Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the chronic malignancies working party of EBMT","volume":"56","author":"Nabergoj","year":"2021","journal-title":"Bonne Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2023.03.005_bib0270","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/bmt.2015.12","article-title":"Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT lymphoma working party","volume":"50","author":"Horstmann","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2023.03.005_bib0275","first-page":"2367","volume":"56","author":"Hayden","year":"2021","journal-title":"Second allogeneic transplants for multiple myeloma: a report from the EBMT chronic malignancies working party. Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2023.03.005_bib0280","article-title":"Graft failure, poor graft function erythroblastopenia: actualization of definitions, diagnosis and treatment: recommendations of the Francophone Society of Bone Marrow Transplantation and cell therapy (SFGM-TC) 2021","author":"Srour","year":"2022","journal-title":"Bull Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2023.03.005_bib0285","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bulcan.2023.03.005_bib0290","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.bulcan.2023.03.005_bib0295","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.03.005_bib0300","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2018.11.030","article-title":"Prognostic performance of the augmented hematopoietic cell transplantation-specific comorbidity\/age index in recipients of allogeneic hematopoietic stem cell transplantation from alternative graft sources","volume":"25","author":"Elsawy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2023.03.005_bib0305","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1182\/bloodadvances.2021004319","article-title":"The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT","volume":"6","author":"Shouval","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bulcan.2023.03.005_bib0310","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.005_bib0315","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","article-title":"Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: a multi-center retrospective study","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bulcan.2023.03.005_bib0320","doi-asserted-by":"crossref","first-page":"605766","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after car t-cell or chemotherapy-based complete remission in b-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.03.005_bib0325","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","article-title":"Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de moelle (SFGM)","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"issue":"1s","key":"10.1016\/j.bulcan.2023.03.005_bib0330","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.bulcan.2018.05.018","article-title":"[Second allogeneic hematopoietic stem cell transplant: guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]","volume":"106","author":"Yafour","year":"2019","journal-title":"Bull Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.005_bib0335","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.bulcan.2023.03.005_bib0340","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41409-022-01777-5","article-title":"Thiotepa\u2013fludarabine\u2013treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial","volume":"57","author":"Finke","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2023.03.005_bib0345","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbmt.2018.01.005","article-title":"Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors","volume":"24","author":"Dul\u00e9ry","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2023.03.005_bib0350","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijrobp.2007.06.037","article-title":"Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation","volume":"70","author":"Heinzelmann","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.bulcan.2023.03.005_bib0355","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1080\/10428194.2018.1542149","article-title":"Second allogeneic hematopoietic cell transplantation for relapse after first allografts","volume":"60","author":"Gyurkocza","year":"2019","journal-title":"Leukemia lymphoma"},{"issue":"12","key":"10.1016\/j.bulcan.2023.03.005_bib0360","first-page":"88","volume":"9","author":"Shimoni","year":"2019","journal-title":"Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the acute leukemia working party of EBMT. Blood Cancer J"},{"issue":"12","key":"10.1016\/j.bulcan.2023.03.005_bib0365","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2023.03.005_bib0375","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.bbmt.2019.04.018","article-title":"Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3\u00a0internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Xuan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2023.03.005_bib0370","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2018.211615","article-title":"Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT acute leukemia working party","volume":"104","author":"Bazarbachi","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.005_bib0380","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.transproceed.2020.06.016","article-title":"Effect of salvage chemotherapy before donor lymphocyte infusion in patients with relapse after allogeneic hematologic stem cell transplantation","volume":"53","author":"Aladag","year":"2021","journal-title":"Transplant Proc"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.005_bib0385","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/ejh.12168","volume":"91","author":"Yan","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2023.03.005_bib0390","doi-asserted-by":"crossref","first-page":"949534","DOI":"10.3389\/fonc.2022.949534","article-title":"Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: a meta-analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.005_bib0395","first-page":"116","volume":"57","author":"Poir\u00e9","year":"2022"},{"issue":"2","key":"10.1016\/j.bulcan.2023.03.005_bib0400","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00277-017-3185-5","article-title":"Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI\u00a0\u2013\u00a0a retrospective multicenter analysis on behalf of the German cooperative transplant study group","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bulcan.2023.03.005_bib0405","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2018.07.005","article-title":"Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation","volume":"72","author":"Sommer","year":"2018","journal-title":"Leukemia Res"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.005_bib0410","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German cooperative transplant study group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2023.03.005_bib0415","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bulcan.2023.03.005_bib0420","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00277-021-04398-y","article-title":"Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial","volume":"100","author":"Amit","year":"2021","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2023.03.005_bib0430","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.bulcan.2023.03.005_bib0425","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1002\/ajh.26405","volume":"97","author":"Gao","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2023.03.005_bib0435","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2023.03.005_bib0440","first-page":"1525","volume":"6","author":"Shouval","year":"2022","journal-title":"The simplified comorbidity index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv"},{"issue":"12s","key":"10.1016\/j.bulcan.2023.03.005_bib0445","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.bulcan.2017.05.009","article-title":"Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)","volume":"104","author":"Yafour","year":"2017","journal-title":"Bulletin Cancer"},{"issue":"1s","key":"10.1016\/j.bulcan.2023.03.005_bib0450","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.bulcan.2018.10.002","article-title":"Donor Lymphocyte Infusions (DLI): guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"106","author":"De Vos","year":"2019","journal-title":"Bulletin Cancer"},{"issue":"12s","key":"10.1016\/j.bulcan.2023.03.005_bib0455","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.bulcan.2021.01.019","article-title":"Palliative care in hematopoietic stem-cell transplanted patients: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"108","author":"Polomeni","year":"2021","journal-title":"Bulletin Cancer"},{"issue":"1","key":"10.1016\/j.bulcan.2023.03.005_bib0230","first-page":"43","volume":"57","author":"Kobayashi","year":"2022","journal-title":"Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed\/refractory acute leukemia after a second transplantation. Bone Marrow Transpalnt"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:38:10Z","timestamp":1757792290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0007455123001492"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deuxi\u00e8me allogreffe (mise \u00e0 jour). Recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle osseuse et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}